

## Epidemiology of Plasmodium-Helminth Co-Infection in Africa: Populations at Risk, Potential Impact on Anemia, and Prospects for Combining Control

Simon Brooker,\* Willis Akhwale, Rachel Pullan, Benson Estambale, Siân E. Clarke, Robert W. Snow, and Peter J. Hotez

London School of Hygiene and Tropical Medicine, London, United Kingdom; Division of Malaria Control, Ministry of Health, Nairobi, Kenya; Institute of Tropical and Infectious Diseases, University of Nairobi, Nairobi, Kenya; KEMRI/Wellcome Trust Research Laboratories, Kenya; University of Oxford, Oxford, United Kingdom; Department of Microbiology and Tropical Medicine, Sabine Vaccine Institute, The George Washington University, Washington, DC

**Abstract.** Human co-infection with *Plasmodium falciparum* and helminths is ubiquitous throughout Africa, although its public health significance remains a topic for which there are many unknowns. In this review, we adopted an empirical approach to studying the geography and epidemiology of co-infection and associations between patterns of co-infection and hemoglobin in different age groups. Analysis highlights the extensive geographic overlap between *P. falciparum* and the major human helminth infections in Africa, with the population at coincident risk of infection greatest for hookworm. Age infection profiles indicate that school-age children are at the highest risk of co-infection, and re-analysis of existing data suggests that co-infection with *P. falciparum* and hookworm has an additive impact on hemoglobin, exacerbating anemia-related malarial disease burden. We suggest that both school-age children and pregnant women—groups which have the highest risk of anemia—would benefit from an integrated approach to malaria and helminth control.

### INTRODUCTION

Malaria poses an enormous public health burden, and > 75% of the global clinical episodes caused by *Plasmodium falciparum* each year are concentrated in Africa.<sup>1</sup> Across the continent, a number of helminth species share the same spatial extents as *P. falciparum*. The most ubiquitous of these are the soil-transmitted helminths (STH: *Ascaris lumbricoides*, *Trichuris trichiura*, and hookworms), which infect more than one third of the continent's population infected at any one time.<sup>2</sup> The schistosomes, *Schistosoma haematobium* and *S. mansoni*, are also endemic throughout the continent, but generally have a much more focal distribution than STH species.<sup>3</sup> In Africa, the overall prevalence of *Wuchereria bancrofti*, which causes lymphatic filariasis (LF), is low<sup>4</sup>, but the disease continues to be of considerable local importance in endemic foci. Finally, onchocerciasis, caused by *Onchocerca volvulus*, is widely distributed throughout the continent.<sup>5</sup>

Spatial congruence of both *P. falciparum* and different helminths remains poorly defined. Preliminary analyses, however, suggest that as many as one quarter of African schoolchildren may be coincidentally at risk of *P. falciparum* and hookworm.<sup>6</sup> This spatial coincidence of risk between these two parasite populations would suggest that co-infection is extremely common, although the public health significance of polyparasitic infection remains a topic for which there are many unknowns. For example, although we know that helminth infections elicit a potent, highly polarized immune response characterized by elevated T-helper cell type 2 (Th2) cytokine and immunoglobulin (Ig)E production,<sup>7</sup> it is unclear whether these responses may modulate human immune responses to malaria and therefore alter susceptibility to clinical disease.<sup>8</sup> Similarly, although malaria and helminth infections are known etiological factors in tropical anemia,<sup>9–11</sup> the extent to which their combined presence might interact to fur-

ther enhance the risk of anemia is poorly understood. Finally, although the relevance of an integrated, non-disease-specific approach to controlling childhood anemia is an increasingly recognized strategy,<sup>12</sup> following a general move toward integrated disease control programs,<sup>13,14</sup> the public health evidence base for combined malaria and helminth control requires better definition.

Two recent reviews have focused on either the epidemiologic<sup>15</sup> or immunologic<sup>8</sup> evidence on *Plasmodium*-helminth interactions. In contrast, this paper quantitatively studies the geography and epidemiology of co-infection and its potential impact on anemia, as well as the exploring the wider implications of co-infection for disease control in Africa.

### PREDICTED PATTERNS OF CO-DISTRIBUTION

The large-scale distributions of parasitic diseases are governed by a number of environmental factors, principally temperature and humidity. We have previously used a combination of temperature, rainfall, and altitude to predict the continental distribution of each of the major STH species.<sup>2</sup> These models suggest that the prevalence of *A. lumbricoides* and *T. trichiura* is greatest in equatorial, central, and west Africa, eastern Madagascar, and southeast Africa, whereas hookworm is more widely distributed across the continent. Other workers have used climate-driven Fuzzy logic models to define the suitability for stable malaria transmission across Africa,<sup>16</sup> and previous estimations<sup>17,18</sup> classify transmission conditions into four classes: zero risk, marginal risk, acute seasonal risk, and stable risk. Combining these different spatial models has previously allowed the estimation of the co-distribution of *P. falciparum* and hookworm and the school-age populations at risk of coincident infection.<sup>6</sup> Here we extend this approach to quantify the populations at risk of infection with both *P. falciparum* and each of the major STH species. In areas of stable endemic malaria transmission between 17.9 and 32.1 million children 5–14 years of age are estimated to be at risk of co-infection with *P. falciparum* and different STH species, with the risk greatest for hookworm (Table 1). Between 5.8 and 9.6 million and 1.6 and 3.4 million children at risk of co-infection in areas of acute marginal

\* Address correspondence to Simon Brooker, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK. E-mail: simon.brooker@lshtm.ac.uk

TABLE 1  
School-aged population (millions) at risk in 2005 of co-infection of *P. falciparum* and STH infection

STH* and <i>P. falciparum</i> † risk	African school-age population (millions) exposed to risk of co-infection
<i>A. lumbricoides</i>	
Stable endemic	17.87 (17.44–18.29)‡
Acute seasonal	5.76 (5.59–5.92)
Marginal	1.61 (1.56–1.66)
<i>T. trichiura</i>	
Stable endemic	21.59 (21.21–21.97)
Acute seasonal	6.99 (6.85–7.14)
Marginal	1.75 (1.70–1.79)
Hookworm	
Stable endemic	32.05 (31.44–32.67)
Acute seasonal	9.55 (9.34–9.78)
Marginal	3.36 (3.18–3.52)

\* Analysis extended from Ref. 5.

† Predicted prevalence of STH based on species-specific models of the relationships between observed prevalence of infection among school-aged children for 1,172 sites across sub-Saharan Africa and satellite-derived environmental data (temperature and vegetation) and elevation data. All surveys were conducted using similar diagnostic techniques (direct smear, typically using the Kato-Katz method) and based on random samples of children in areas where no control measures have previously been undertaken. For further details, see Brooker and others.<sup>2</sup>

‡ Based on a climate-driven model of malaria suitability that has previously been used to classify populations exposed to risk of stable malaria and epidemic malaria (Craig et al., 1999). This model provides fuzzy climate suitability (FCS) values, ranging from unsuitable [0] to completely suitable [1] for stable *P. falciparum* transmission. We adopted a modified classification of this risk criteria used in previous estimations of childhood populations at risk of different transmission conditions<sup>17,18</sup>; zero risk [FCS = 0], marginal risk [FCS > 0 < 0.25], acute seasonal transmission [FCS > 0.25 < 0.75] and stable endemic transmission [FCS > 0.75]. The FCS risk classes were additionally adjusted for the suppressive effects of urbanization on malaria transmission using the approach developed by Hay and others.<sup>17</sup>

§ Populations at risk based on projected 2005 school-age population estimates, which were abstracted from the Gridded Population of the World version 3.0<sup>101</sup> and country-specific medium variant population growth rates and proportions of the population 5–14 years of age from the United Nations Population Division–World Population Prospects database.<sup>102</sup> The combined STH- and malaria-risk and population models were used to estimate the populations at risk of co-infection. To estimate the combined risk of STH and *P. falciparum*, independence between species was assumed. 95% confidence intervals are based on those calculated for the predicted STH prevalence. For further details, see Brooker and others.<sup>6</sup>

seasonal transmission and marginal transmission, respectively. This analysis indicates that the coincidental malaria-STH at-risk population is greatest for hookworm than either *A. lumbricoides* or *T. trichiura*. Schistosomiasis has a more focal distribution caused by spatial heterogeneities in snail dynamics and human behavior,<sup>3</sup> making the prediction of co-distribution with malaria more difficult to assess. Finally, many of the areas endemic for LF and onchocerciasis are also affected by malaria,<sup>19</sup> although this remains to be reliably quantified.

## EPIDEMIOLOGY OF CO-INFECTION

Patterns of single parasite species infection of STH or *P. falciparum* have been well documented during classic epidemiology. Both types of parasites exhibit marked age dependency in infection patterns. Age-stratified epidemiologic studies indicate that the prevalence of asymptomatic *Plasmodium* infections increases in early childhood, beginning to decline with the gradual acquisition of immunity. The precise rate and age at which immunity is acquired is exposure dependent, but in areas of stable transmission infections in adulthood are generally low (Figure 1). In contrast, the prevalence of STH and schistosomiasis infections increases throughout childhood to a relatively stable plateau or show a slight decrease in adulthood. The highest prevalence of LF generally occurs during adulthood, although there has been increasing appreciation of LF as an important public health problem among children and adolescents.<sup>20</sup> In contrast to




FIGURE 1. Typical age profiles of prevalence of *P. falciparum* infection, hookworm and *S. mansoni*. Data taken from Ashford and others<sup>103</sup> and Kabatereine and others.<sup>104</sup>

such characteristic age dependency, age-specific patterns of *O. volvulus* show strong variation according to localities.<sup>21</sup>

Helminths have an overdispersed distribution, with most individuals harboring few or no worms, and the majority of the worm population found in a minority of individuals<sup>22</sup>; it is within this group that most of the morbidity occurs. Similar patterns of overdispersion are also evident for *P. falciparum* infections: recent modeling of parasite prevalence and the basic reproduction rate of infection suggests that 20% of children in a community receive 80% of new infections in a community.<sup>23</sup> Both malaria and helminth infections have a tendency to cluster within certain families and households.<sup>24,25</sup>

In contrast to the well-characterized patterns of single parasite infections, we know surprisingly little about the patterns and risk factors of co-infection within communities. The occurrence of co-infection will depend on 1) the overall prevalence of individual species and 2) the degree of association between different species. If infection with *P. falciparum* and helminths are independent, occurrence of co-infection is simply determined by the relative frequency of individual species. Thus, the age patterns of co-infection will depend on the age-specific prevalence rates as predicted by simple probability. However, if co-infection is either synergistic or antagonistic, occurrence of both parasites would be significantly different from that predicted by individual chance encounters with either infection. Such associations may arise because of biologic associations, whereby the presence of one species promotes or inhibits the establishment and/or survival of the second species, potentially through immune modulation.<sup>8</sup> Alternatively, co-infection may reflect concurrence of common socio-economic and/or environmental risk factors promoting survival of both species.<sup>15,26</sup> At present, there are too few studies able to disentangle the relative importance of different risk factors for co-infection and detailed epidemiologic studies are clearly warranted.

However, on what we currently know about the epidemiology of co-infection, it is suggested that school-age children, rather than preschool children or adults, are most at risk of plasmodium–helminth co-infection (Figure 1), and thereby at greatest risk of the consequences of co-infection. The next section provides a brief review of the immunologic consequences of co-infection, before turning to the impact of co-infection on hemoglobin levels.

## IMMUNE CONSEQUENCES OF CO-INFECTION

The successful resolution of *Plasmodium* infection requires a coordinated succession from a T-helper cell type 1 (Th1) to a Th2 type response, and anything that upsets the timing or balance of this process can lead to chronic or severe infection.<sup>27</sup> The Th2-skewed immune profile and profound cellular hyporesponsiveness induced by chronic helminth infection<sup>7</sup> might therefore be expected to affect the course of *Plasmodium* infection. This hypothesis has led researchers to study the interactions between *Plasmodium* and helminth infection. However, limited observational studies thus far have provided conflicting accounts of the effects of chronic helminth infection on host immune responses to malaria. Early studies suggested that *Ascaris lumbricoides* infection might be protective against malarial disease,<sup>28,29</sup> in contrast to several later reports, which suggested that STH infections may increase the risk of malaria infection.<sup>26,30–33</sup> Conversely, a potential protective effect on malaria of light schistosome infection has been reported in Senegal and Mali.<sup>34,35</sup> Other studies have noted a difference in the development of severe malaria between helminth-infected and uninfected individuals, with several studies from Thailand suggesting a protective effect for *A. lumbricoides* infection on the risk of cerebral malaria and acute renal failure,<sup>36–39</sup> although again this is in contrast to a study in Senegal, which suggested a positive association between infection with *A. lumbricoides* and the occurrence of severe malaria.<sup>33</sup> Thus, epidemiologic observations now suggest a range of scenarios in which helminth infections may increase susceptibility to *Plasmodium* infection but may also under certain circumstances protect against severe malaria.<sup>8</sup> The potential immuno-regulatory mechanisms by which helminths may alter immune responses to malaria are summarized in Figure 2. Despite the biologic plausibility of syner-

gism and antagonism and the somewhat contradictory evidence,<sup>15</sup> the precise relationship between co-infection and clinical malaria continues to remain difficult to empirically determine, and definitive studies are urgently needed to resolve the issue.

Figure 2 also shows the possible mechanisms by which malaria and helminths may cause anemia. The next section expands on these mechanisms and assesses the epidemiologic evidence on the potential impact of co-infection on hemoglobin levels.

## IMPACT OF CO-INFECTION ON ANEMIA

Anemia is one of the most widespread and common health condition afflicting individuals living in the tropics, and in Africa, it contributes to 23% of nutrition-related disability-adjusted life years.<sup>40</sup> The consequences of anemia are particularly severe for children and pregnant women.<sup>12,41</sup> Chronic anemia during childhood is associated with impairments in physical growth, cognition, and school performance,<sup>42</sup> whereas severe anemia accounts for up to one half of the malaria-attributable deaths in children younger than 5 years of age.<sup>43</sup> Maternal anemia is associated with low birth weight and increased maternal morbidity and mortality.<sup>38,44</sup> Although the etiology of anemia is complex and multifactorial in origin, parasitic diseases, including *P. falciparum* and helminth infections, have long been recognized as major contributors to anemia in endemic countries.

Recent meta-analyses of malaria intervention trials among African children provided compelling evidence that both symptomatic and asymptomatic malaria contributes substantially to anemia in endemic regions.<sup>43,45</sup> Malaria contributes to reduce hemoglobin concentrations through a number of




FIGURE 2. *Plasmodium*–helminth co-infection: hypothesized mechanisms through which helminths may alter the risk of malarial infection and disease and the mechanisms through which anemia arises. Chronic helminth infection induces a T-helper 2 (Th2) cytokine response, which may impose cross-regulatory effects on the development of an appropriate pro-inflammatory response to initial malaria infection,<sup>105–108</sup> and skew anti-*Plasmodium* antibody responses toward the production of non-cytophilic immunoglobulins ineffective against malaria (IgG4 and IgGM), instead of cytophilic ones necessary for immunity (IgG1 and IgG3).<sup>109,110</sup> However, induction of an anti-inflammatory immunosuppressive network may in fact prevent severe pathology in the later stages of malaria infection, with high levels of helminth-induced interleukin (IL)-10<sup>111–114</sup> acting to down-modulate the effects of interferon (IFN)-γ and tumor necrosis factor (TNF)-α, thus reducing malaria pathology.<sup>8</sup> Alternatively, sequestration of infected red blood cells may be prevented through IgE-mediated activation of the CD23/NO pathway.<sup>115</sup> Adapted and expanded from Hartgers and Yazdanbakhsh.<sup>8</sup>

mechanisms, principally by destruction and removal of parasitized red cells and the shortening of the life span of non-parasitized red cells, and decreasing the rate of erythrocyte production in the bone marrow.<sup>46</sup> Some of the mechanisms that cause anemia during malaria are associated more with the acute clinical states (e.g., hemolysis or cytokine disturbances), whereas chronic or repeated infections are more likely to involve dyserythropoiesis.<sup>9</sup> Data among Ghanaian schoolchildren suggest that hemoglobin concentration was 9 g/L lower among children with asymptomatic *P. falciparum* infection than uninfected children.<sup>47</sup> Although this finding cannot be extrapolated to all settings, these results suggest that asymptomatic parasitemia may be associated with a marked reduction in hemoglobin concentration among older children who are also at highest risk of helminth infection.

The effects of infection with a single helminth species on the risk of anemia are well documented, with risk correlated with infection intensity.<sup>11,48,49</sup> A recent study among Filipino schoolchildren highlights how even low-intensity multiple helminth infections enhance anemia risk.<sup>50</sup> Hookworm causes iron deficiency anemia through the process of intestinal blood loss.<sup>10</sup> Schistomes also cause anemia by chronic blood loss, as eggs penetrate the wall of the bowel (in intestinal schistosomiasis) and the urinary tract (in urinary schistosomiasis).<sup>11</sup> Like malaria, anemia caused by schistosomes can additionally arise from destruction of red blood cells and/or dyserythropoiesis. *Ascaris lumbricoides* and *Trichuris trichuria* typically have little impact on iron status.<sup>51</sup>

Based on the distinct mechanisms by which malaria and hookworm and schistosomes reduce hemoglobin levels, it can be speculated that their combined presence might interact to enhance the risk of anemia. However, little is known about the impact of co-infection on anemia among different age groups. We have approached this paucity of data by re-analyzing available data from Kenya to study the association between co-infection and hemoglobin levels (Figure 3). Data for preschool children indicate that co-infection with *P. falciparum* and heavy hookworm is associated with significantly lower hemoglobin concentration than single infections with either *P. falciparum* or hookworm (Figure 3A). Among schoolchildren, hemoglobin is 4.2 g/L (95% CI, 3.1–5.2 g/L) lower among children harboring co-infections than single species infections (Figure 3B). In contrast, no significant difference was observed among pregnant women, although both malaria and hookworm alone had a significant impact on hemoglobin levels (Figure 3C). Although these data are suggestive of an additive impact of co-infection on anemia in certain age groups, it should be noted that such associations may be confounded by socio-economic, genetic, and nutritional factors and that the effects of co-infection may vary by malaria and helminth transmission intensities.<sup>52</sup> Consequently, randomized controlled trials of combining malaria- and helminth-specific interventions aimed at establishing the contribution of co-infection on anemia should be conducted in a range of transmission settings.

In the absence of further data on the effects of co-infection on anemia, the significance of these re-analyzed data must be treated with caution but should not be ignored either. Overlooking the impact of co-infection may underestimate the disease burden of malaria. For young children, co-infection may be relatively unimportant because, although the impact of co-infection on hemoglobin levels is extremely marked, co-

infection occurs relatively infrequently (only 3.5% of preschoolers harbored both heavy hookworm and *P. falciparum* infection). Among school-age children, the picture appears different, however: 35.2% of school-age children in the Kenyan study harbored both heavy hookworm and *P. falciparum* infection. On the assumptions that these data are representative, the impact of co-infection on anemia may be associated with a significant disease burden among African school-age children in areas of high parasite transmission. In numerical terms, up to 32 million African school-age children in areas of stable malaria transmission may be at risk of heavy hookworm and *P. falciparum* infection and thus at enhanced risk of anemia.<sup>6</sup> The situation in settings with low parasite transmission or adequate nutritional intake is currently unknown and merits exploration. The next section discusses potential approaches to combining malaria and helminth interventions aimed at reducing the anemia-related disease burden associated with co-infection.

## COMBINED CONTROL

Several effective malaria control interventions currently exist, including residual house spraying, insecticide-impregnated materials (particularly bed nets), and antimalarial drugs. Increasing political and financial support for malaria control, as well as renewed emphasis on population-based anthelmintic treatment,<sup>14</sup> makes a combined malaria-helminth approach to control timely. Although the appropriateness of different intervention strategies will depend on a complex of interacting factors that determine the epidemiology of infection and availability of delivery mechanisms, there exist multiple potential for combining malaria control with helminth control (Table 2).

**Infants and preschool children.** Although early diagnosis and prompt treatment is a vital element of malaria control,<sup>53</sup> chemoprophylaxis and insecticide-treated nets (ITNs) have been shown to be highly effective at reducing malaria-related mortality and morbidity.<sup>54–56</sup> A promising new alternative malaria control strategy is intermittent preventive treatment in infants (IPTi).<sup>57</sup> Here, treatment doses of sulfadoxine/pyrimethamine (SP) are delivered to infants, irrespective of infection status, at the time of routine vaccination during the first year of life. Additionally, studies in west Africa have shown that seasonal IPT could be an effective malaria prevention strategy among children younger than 5 years of age in areas of seasonal malaria transmission,<sup>58,59</sup> but further study is needed to determine whether this is a practical approach to malaria control.<sup>60,61</sup> In terms of the impact of IPTi on anemia, a trial among Tanzania infants found a 50% protective efficacy against severe anemia.<sup>62</sup> Among Ghanaian infants, IPTi was associated with a significantly higher mean packed cell volume at 12 months of age, but was associated with slightly lower volumes at 18 months.<sup>63</sup>

Regarding helminth control among preschool children, the benefits of deworming are increasingly appreciated. For example, recent evidence from Zanzibar indicates that anthelmintic treatment significantly reduced the prevalence of anemia and stunting among preschoolers who received mebendazole every 3 months for 1 year.<sup>64</sup> On the basis of available evidence on the effectiveness of treatment and the safety of providing to young children, WHO now recommends, in ar-



FIGURE 3. The relationship between plasmodia-hookworm co-infection and mean hemoglobin concentration in Kenya based on re-analysis of published data. **A**) Preschool children: 460 children: 61.5% were uninfected; 30.9% infected with *P. falciparum* alone; 4.1% with heavy hookworm (eggs/gram feces [epg] > 2,000; 3.5% with both, based on Brooker and others<sup>116</sup> **B**, School-age children: 392 children: 19.1% were uninfected; 27.8% infected with *P. falciparum* alone; 17.9% with heavy hookworm (epg > 2,000); and 35.2% with both, based on Stephenson and others.<sup>48</sup> **C**, Pregnant women: 251 women: 68.5% were uninfected; 21.1% infected with *P. falciparum* alone; 6.0% with heavy hookworm (epg > 2,000); and 4.4% with both, based on Shulman and others.<sup>117</sup> Mean hemoglobin based on regression modeling adjusting for age, sex, nutrition status, socioeconomic status (preschool children), and gestation (pregnant women). Error bars indicate 95% confidence intervals.

eas of high helminth prevalence, to provide anthelmintic treatment to children from the age of 12 months.<sup>65,66</sup> Thus, anthelmintic treatment could potentially be co-administered with IPT to children 1–5 years of age in areas of seasonal malaria transmission. Based on current guidelines, deworming is unable to be provided as part of IPTi activities.

**School-age children.** The delivery of malaria chemoprophylaxis to schoolchildren through schools was widespread in Africa during the 1950s and 1960s and resulted in significant reductions in parasitemia and rates of anemia and clinical malaria attacks.<sup>45,67</sup> However, regular chemoprophylaxis in malaria-endemic countries proved to be unsustainable, largely because of problems in drug distribution and financing and concerns about the potential emergence of drug resistance.<sup>68</sup> Today there is a renewed interest in the potential of the education sector to address the impact of malaria on school-age children.<sup>69,70</sup> A recent study of the impact of ITNs (permethrin) on the health of adolescent schoolgirls in western Kenya found that ITNs were associated with an increase in hemoglobin concentrations (0.34 g/dL; 95% CI = 0.02, 0.66).<sup>71</sup> A study in Tanzania showed the effectiveness of teachers in recognizing and treating malaria in school children,<sup>72</sup> and a study in Malawi showed the effectiveness of presumptive treatment in reducing malaria-related mortality among schoolchildren where teachers were trained to use “first aid kits” to dispense SP treatment to symptomatic children.<sup>73</sup>

IPT may also prove a valuable approach in older children in preventing malaria-related anemia. A trial was recently completed among schoolchildren in a high malaria transmission area of western Kenya evaluating the effect of IPT using SP combined with amodiaquine on children’s hemoglobin concentrations and their ability to concentrate in class, whereby children were provided with a curative treatment dose every term during the school year, regardless of infection status. Preliminary results indicate that IPT almost halves (protective efficacy 55%; 95% CI: 20–74%) the occurrence of anemia and reduces malaria parasitemia by 90% (95% CI: 82–95%) (Clarke and others, unpublished data). Future work will address the effectiveness of the approach in a range of transmission settings and the operational feasibility of integrating the approach into current school health programs, including provision of IPT by teachers.

In contrast to the operational uncertainties and absence of guidance as to good practice for malaria control in schools, global efforts are already underway to control helminth-related morbidity among school-age children through the combined delivery of praziquantel to treat schistosomiasis and benzimidazole anthelmintics, albendazole, and mebendazole to treat STH infections. Because the most intense helminth infections and related illnesses occur at school age<sup>74,75</sup> and infection can have adverse consequences for health and development,<sup>76</sup> many of which is rapidly reversed by treatment, school-age children are the natural targets for treatment. In addition, school-based treatment delivery programs offer several cost advantages because of the use of the existing school infrastructure and the fact that schoolchildren are accessible through schools.<sup>77</sup>

Thus, school-based deworming programs may provide a possible entry point for combined delivery of IPT and anthelmintics or at least a way of sharing resources to do so, with limited increase in operational costs. Combined school-based

TABLE 2  
Potential malaria and helminth control strategies which could be combined

Population	Malaria	STH and schistosomiasis	Lymphatic filariasis	Onchocerciasis
Infants and preschool children	IPTi/IPTc*	Regular treatment with ABZ and PQZ†	NR	NR
School-age children	IPT in schools* Health education to promote ITN use and prompt effective treatment	Regular treatment with ABZ and PQZ Health education on prevention Improved sanitation		
Pregnant women	IPTp ITNs	Regular treatment with ABZ and PQZ‡		
Community-based control	ITNs Health education to promote ITN use and prompt effective treatment	Regular treatment with ABZ and PQZ Health education on prevention Improved sanitation	Annual CDT with ABZ plus IVM§ or with ABZ plus DEC¶ Vector control where appropriate	CDT treatment with IVM Vector control where appropriate

Expanded from Ref. 19.

\* Not yet recommended by WHO and is the subject of ongoing evaluation.

† To children  $\geq 1$  year of age.

‡ In second and third trimester of pregnancy.

§ In areas co-endemic with onchocerciasis.

¶ In non-endemic onchocerciasis areas.

IPTi, intermittent preventive treatment in infants; IPTc, intermittent preventive treatment in young children; IPTp, intermittent preventive treatment in pregnancy; ITNs, insecticide treated nets; ABZ, albendazole; PQZ, praziquantel; CDT, community-directed treatment; IVM, ivermectin; DEC, diethylcarbamazine; NR, not recommended.

parasite control is not new, however, and many useful lessons can be learned from past experiences.<sup>78</sup> Health promotion activities and teaching within schools to encourage good hygiene practices and awareness of malaria prevention methods, such as the use of sleeping under an ITN, will help support and maintain health gains.

**Pregnant women.** The current recommended control strategy for malaria during pregnancy in areas of stable transmission is IPT with SP, given during the second and third trimester,<sup>66</sup> which provides benefits in terms of reduced rates of maternal anemia<sup>79</sup> and malaria morbidity.<sup>80,81</sup> The use of ITNs, which have a well-documented beneficial impact on pregnancy outcomes,<sup>82</sup> is also advocated. Although screening and treatment of hookworm infection in pregnant women is recommended,<sup>83</sup> there are surprisingly very few published studies reporting the impact of deworming on maternal health or pregnancy in Africa. Trials among pregnant women in Sierra Leone<sup>84</sup> and Peru<sup>85</sup> showed that deworming resulted in increased hemoglobin concentrations, and a study in Nepal found that deworming resulted in improvements in maternal iron status, birth weight, and perinatal survival.<sup>86</sup> Further study of the benefits of deworming among African pregnant women is clearly needed. Although co-infection was not found to be associated with lower hemoglobin among Kenyan pregnant women (Figure 3C), the detrimental effects of malaria and hookworm alone—together with the potential impact of schistosomiasis in pregnancy<sup>87</sup>—warrants the evaluation of the combined use of IPT with SP and anthelmintic treatment. The potential additive benefits of combining interventions targeted at anemia is shown by a study in Sri Lanka that showed that mebendazole given in combination with iron-folate can improve hemoglobin and iron status more than iron-folate alone.<sup>88</sup>

**Community-based control.** ITN distribution and residual house spraying are the main community-based malaria control strategies. In the more rural areas Africa, the same *Anopheles* mosquito species transmits both LF and malaria; in most urban and semi-urban areas, *Culex* spp. mosquitoes are the major vectors for *W. bancrofti*. Pilot studies indicate

that ITNs can impact on vector biting densities of both *Anopheles* spp. and *Cx. quinquefasciatus* and on overall transmission of *W. bancrofti*.<sup>89,90</sup> For this reason, it has been suggested that the global LF programs lends itself particularly well to linkage with malaria control programs in areas co-endemic for LF and malaria.<sup>19</sup>

The cornerstone of onchocerciasis control is larviciding of *Simulium* (blackfly) vector breeding grounds and mass drug administration with ivermectin.<sup>5,91</sup> Since 1995, the African Program for Onchocerciasis Control has implemented community-directed treatment (CDT) with ivermectin, whereby communities themselves appoints local drug distributors.<sup>91</sup> CDT has also been a feature of the Global Program to Eliminate LF, whereby communities are treated with albendazole and ivermectin in areas where onchocerciasis is endemic and albendazole and diethylcarbamazine (DEC) elsewhere.<sup>92</sup> The CDT strategy is increasingly being used as platform to combining other community-based health interventions, including malaria interventions.<sup>19</sup> Such linkage can help maintain high coverage levels achieved through onchocerciasis and LF CDT-based control. For example, recent experience in Nigeria suggests that integrated distribution by community volunteers of anthelmintics against LF and onchocerciasis, as well as ITNs, resulted in an increased net uptake.<sup>93</sup> These observations provide early indication of the feasibility of ITN distribution through a mass treatment campaign for helminths.

## PROPOSED RESEARCH AGENDA

If there was a move toward a combined strategy to malaria-helminth control, there is a need to broaden the scope of research. Clearly the epidemiology of co-infection must be better studied before appropriate recommendations for the appropriate epidemiologic setting can be made. The relevance of different parasite-specific interventions will vary according to different transmission intensity conditions.<sup>94</sup> For example, IPTi may only be appropriate in areas of stable or

seasonal malaria transmission but not in areas of low transmission. Moreover, whether iron supplementation should be withheld in young children is crucially dependent on understanding of the relative risk of iron deficiency and the rate of exposure to malaria, such that recommendations for iron supplementation cannot be based on a limited number of studies but need to be tailored to the nutritional status of the population and the intensity of malaria transmission.<sup>95</sup> Finally, the impact of different mixes of interventions may depend on the intensity of malaria and helminth transmission—a single approach to combined control is highly unlikely. To guide rational control, a number of key issues need to be empirically studied in a range of transmission and operational settings. As a first effort, we propose the study of the following key areas.

First, to better define the consequences of co-infection-related anemia requires more detailed analysis of empirical data on hemoglobin concentrations among different population groups to study the relationship between malaria-helminth co-infection on hemoglobin and iron deficiency anemia. The recently launched studies of IPT can potentially be combined with deworming to provide a more powerful platform to qualify the consequences of co-infection on anemia more precisely. There is also a clear need to look at mechanisms of this process in a co-infected individual. Therefore, measurements of intestinal blood (fecal protoporphyrin), shortened red blood cell (RBC) half-life, iron-binding capacity, splenic sequestration, and dyserythropoiesis should be examined in the polyparasitized; it may be more than additive. Such work is important to better define the contribution of co-infection to the public health burden in Africa and would also allow for a realistic framework to understand how to target intervention needs, as well as provide a rubric against which to measure progress toward national and international public health goals.

Second, to help identify priority areas for combined control, there is a requirement to delineate and understand the spatial overlap and co-endemicity of malaria-helminth infections. Mapping of malaria has undergone a renaissance after an increased recognition that malaria interventions such as IPTi and vector control approaches must be guided by effective cartography of malaria endemicity risk.<sup>94</sup> In addition, the value of a geographical perspective to helminth epidemiology and control has long been recognized and has been supported by the recent use of GIS and remote sensing.<sup>2,3,96</sup> Geographical congruency of different parasite species can be based initially on climate-based disease risk maps, such as those presented here used to model plasmodium-STH co-distribution.<sup>6</sup> Such maps, however, belie the geographical variation evident at the community level, which is difficult to capture with existing risk models, and there is a requirement for more detailed empirical data collected through structured field surveys. For example, in light of recent evidence suggestive of a negative spatial association between *W. bancrofti* and *P. falciparum* in west Africa,<sup>97</sup> the distribution of LF and malaria at local scales urgently needs to be better determined. Moreover, it remains unclear how patterns of co-distribution actually relate to co-infection, and how distributions of co-infection vary with environmental and socio-economic heterogeneities. Interpretation of future survey data would, in turn, be facilitated by geostatistical models that will help to identify significant spatial risk factors and predict patterns of

co-endemicity and co-infection. To date, only one study has attempted to model the spatial occurrence of co-infection,<sup>98</sup> and it showed that it was possible to predict spatial patterns of *S. mansoni* and hookworm. An improved understanding of spatial risk factors will allow the projection of co-endemicity on the basis of remotely sensed satellite data to allow for improved co-infection disease burden estimates. Newly refined endemicity maps will provide the basis for rational implementation of combined control by deriving more accurate commodity and budget estimates for different intervention types and mixes within countries.

Third, because the mix of optimal interventions will depend on the level of parasite transmission, there is a need to determine the cost-effectiveness of different intervention combinations in a range of endemicity conditions. An anticipated benefit of combining malaria and helminth control in Africa would be the health gains that could result from reducing anemia. As indicated, possible options include the linkage of IPTp with deworming to tackle maternal anemia and the combined delivery of IPT and deworming through schools to improve hemoglobin levels. In addition to these immediate health impacts, there may also be benefits on, often neglected, non-health benefits, including cognition and school performance.

Combining different interventions may yield what economists call economies of scope, thereby resulting in lower average costs.<sup>99</sup> However, this may also cause diseconomies of scope (increasing average costs), whereby adding more treatments overloads capacity, and the current intervention is delivered less efficiently.<sup>100</sup> This aspect deserves critical attention as integrated programs are rolled out. There are also a number of operational research questions that would require attention, including optimizing delivery systems, identifying appropriate drug combinations, devising appropriate monitoring, and evaluation. Finally, the safety of different IPT and anthelmintic drug combinations needs to be firmly established before interventions can be rolled out.

## CONCLUSIONS

Early hypotheses on malaria-helminth interactions arose from studies documenting the potent immune responses evoked by helminths and the Th1/Th2 hypothesis. More recent attention has focused on the potential impact of co-infection on hemoglobin levels and the relevance of an integrated approach to controlling childhood anemia. However, the epidemiologic evidence base on co-infection is currently inadequate, and there is a need to adopt a credible, data-driven approach to resolve key scientific and programmatic questions. We have presented preliminary analysis of available data to study issues, but it is clear that further detailed study in a range of parasite transmission settings is warranted. We would argue that co-infection and its impact on anemia should be studied in the same rigorous way that single parasite species has been studied, thereby allowing the development of a realistic framework to prioritize resources and to anticipate potential intervention impact. Several opportunities for combining malaria control with anthelmintic treatment currently exist, and we would suggest that combined intervention would be particularly relevant for vulnerable populations who are at the highest risk for anemia such as

children and pregnant women. However, relevant interventions should be tailored to the epidemiologic conditions so that resources are optimally targeted.

Received January 5, 2007. Accepted for publication February 23, 2007.

Acknowledgments: The authors thank Lani Stephenson and Caroline Shulman for allowing us to re-analyse their data.

Financial support: SB is supported by a Wellcome Trust Research Career Fellowship (081673). SB and PJH acknowledge support of the Albert B. Sabin Vaccine Institute's Human Hookworm Vaccine Initiative (HHVI) funded by the Bill and Melinda Gates Foundation. RP is supported by a Medical Research Council DTA-funded studentship. RWS is a Wellcome Trust Principal Research Fellow (079080) and acknowledges the support of the Kenyan Medical Research Institute.

Authors' addresses: Simon Brooker, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK, Telephone: 44-207-927-2614, E-mail: simon.brooker@lshtm.ac.uk. Willis Akhwale, Division of Malaria Control, Ministry of Health, PO Box 20750, Nairobi, Kenya, E-mail: head.nmcp@domkenya.or.ke. Rachel Pullan, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK, E-mail: rachel.pullan@lshtm.ac.uk. Benson Estambale, Institute of Tropical and Infectious Diseases, University of Nairobi, PO Box 19676-00202, Nairobi, Kenya, E-mail: bestambale@uonbi.ac.ke. Sian Clarke, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK, E-mail: sian.clarke@lshtm.ac.uk. Robert W Snow, Malaria Public Health and Epidemiology Group, Centre for Geographic Medicine, KEMRI/Wellcome Trust Research Laboratories, Nairobi, Kenya, E-mail: rsnow@nairobi.kemri-wellcome.org. Peter J Hotez, Department of Microbiology and Tropical Medicine, The George Washington University, 2300 Eye Sreet, NW, Washington, DC 20037 and Sabine Vaccine Institute, Telephone: 202-994-3532, E-mail: mtmpjh@gwumc.edu.

## REFERENCES

1. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI, 2005. The global distribution of clinical episodes of *Plasmodium falciparum* malaria. *Nature* 434: 214–217.
2. Brooker S, Clements ACA, Bundy DAP, 2006. Global epidemiology, ecology and control of soil-transmitted helminth infections. *Adv Parasitol* 62: 221–261.
3. Brooker S, 2007. Spatial epidemiology of human schistosomiasis in Africa: risk models, transmission dynamics and control. *Trans R Soc Trop Med Hyg* 101: 1–8.
4. Michael E, Bundy DAP, 1997. Global mapping of lymphatic filariasis. *Parasitol Today* 13: 472–476.
5. Boatin B, Richards F, 2006. Control of onchocerciasis. *Adv Parasitol* 61: 349–394.
6. Brooker S, Clements AC, Hotez PJ, Hay SI, Tatem AJ, Bundy DA, Snow RW, 2006. The co-distribution of *Plasmodium falciparum* and hookworm among African schoolchildren. *Malaria J* 5: 99.
7. Maizels RM, Balic A, Gomez-Escobar N, Nair M, Taylor MD, Allen JE, 2004. Helminth parasites—masters of regulation. *Immunol Rev* 201: 89–116.
8. Hartgers FC, Yazdanbakhsh M, 2006. Co-infection of helminths and malaria: modulation of the immune responses to malaria. *Parasite Immunol* 28: 497–506.
9. Menendez C, Fleming AF, Alonso PL, 2000. Malaria-related anaemia. *Parasitol Today* 16: 469–476.
10. Hotez PJ, Brooker S, Bethony JM, Bottazzi ME, Loukas A, Xiao S, 2004. Hookworm infection. *N Engl J Med* 351: 799–807.
11. Friedman JF, Kanzaria HK, McGarvey ST, 2005. Human schistosomiasis and anemia: the relationship and potential mechanisms. *Trends Parasitol* 21: 386–392.
12. Crawley J, 2004. Reducing the burden of anemia in infants and young children in malaria-endemic countries of Africa: from evidence to action. *Am J Trop Med Hyg* 71: 25–34.
13. Hotez PJ, Molyneux DH, Fenwick A, Ottesen E, Ehrlich Sachs S, Sachs JD, 2006. Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. *PLoS Med* 3: e102.
14. WHO, 2006. *Preventive Chemotherapy in Human Helminthiasis. Coordinated Use of Anthelmintic Drugs in Control Interventions: A Manual for Health Professionals and Programme Managers*. Geneva: World Health Organization.
15. Mwangi TW, Bethony JM, Brooker S, 2006. Malaria and helminth interactions in humans: an epidemiological viewpoint. *Ann Trop Med Parasitol* 100: 551–570.
16. Craig MH, Snow RW, le Sueur D, 1999. A climate-based distribution model of malaria transmission in sub-Saharan Africa. *Parasitol Today* 15: 105–111.
17. Hay SI, Guerra CA, Tatem AJ, Atkinson PM, Snow RW, 2005. Urbanization, malaria transmission and disease burden in Africa. *Nat Rev Microbiol* 3: 81–90.
18. Snow RW, Craig MH, Newton CRJC, Steketee R, 2003. *The Public Health Burden of Plasmodium falciparum Malaria in Africa: Deriving the Numbers. Disease Control Priorities Project*. Bethesda, MD: Fogarty International Center, National Institutes of Health.
19. Molyneux DH, Nantulya VM, 2004. Linking disease control programmes in rural Africa: a pro-poor strategy to reach Abuja targets and millennium development goals. *BMJ* 328: 1129–1132.
20. Witt C, Ottesen E, 2001. Lymphatic filariasis: an infection of childhood. *Trop Med Int Health* 6: 582–606.
21. Filipe J, Boussinesq M, Renz A, Collins R, Vivas-Martinez S, Grillet M, Little M, Basanez M, 2005. Human infection patterns and heterogeneous exposure in river blindness. *Proc Natl Acad Sci USA* 102: 15265–15270.
22. Anderson RM, May RM, 1985. Helminth infections of humans: mathematical models, population dynamics, and control. *Adv Parasitol* 24: 1–101.
23. Smith DL, Dushoff J, Snow RW, Hay SI, 2005. The entomological inoculation rate and *Plasmodium falciparum* infection in African children. *Nature* 438: 492–495.
24. Brooker S, Alexander N, Geiger S, Moyeed RA, Stander J, Fleming F, Hotez PJ, Correa-Oliveira R, Bethony J, 2006. Contrasting patterns in the small-scale heterogeneity of human helminth infections in urban and rural environments in Brazil. *Int J Parasitol* 36: 1143–1151.
25. Snow RW, Schellenberg JR, Peshu N, Forster D, Newton CR, Winstanley P, Mwangi I, Waruiru C, Warn PA, Newbold C, Marsh K, 1993. Periodicity and space-time clustering of severe childhood malaria on the coast of Kenya. *Trans R Soc Trop Med Hyg* 87: 386–390.
26. Tshikuka JG, Scott ME, Gray-Donald K, Kalumba ON, 1996. Multiple infection with *Plasmodium* and helminths in communities of low and relatively high socio-economic status. *Ann Trop Med Parasitol* 90: 277–293.
27. Riley EM, Wahl S, Perkins DJ, Schofield L, 2006. Regulating immunity to malaria. *Parasite Immunol* 28: 35–49.
28. Murray MJ, Murray AB, Murray MB, Murray CJ, 1977. Parotid enlargement, forehead edema, and suppression of malaria as nutritional consequences of ascariasis. *Am J Clin Nutr* 30: 2117–2121.
29. Murray J, Murray A, Murray M, Murray C, 1978. The biological suppression of malaria: an ecological and nutritional interrelationship of a host and two parasites. *Am J Clin Nutr* 31: 1363–1366.
30. Nacher M, Singhasivanon P, Yimsamran S, Manibunyon W, Thanayanich N, Wuthisen R, Looareesuwan S, 2002. Intestinal helminth infections are associated with increased incidence of *Plasmodium falciparum* malaria in Thailand. *J Parasitol* 88: 55–58.
31. Spiegel A, Tall A, Raphenon G, Trape JF, Druilhe P, 2003. Increased frequency of malaria attacks in subjects co-infected by intestinal worms and *Plasmodium falciparum* malaria. *Trans R Soc Trop Med Hyg* 97: 198–199.
32. Sokhna C, Le Hesran JY, Mbaye PA, Akiana J, Camara P, Diop M, Ly A, Druilhe P, 2004. Increase of malaria attacks among



- children presenting concomitant infection by *Schistosoma mansoni* in Senegal. *Malaria J* 3: 43.
33. Le Hesran JY, Akiana J, Ndiaye el HM, Dia M, Senghor P, Konate L, 2004. Severe malaria attack is associated with high prevalence of *Ascaris lumbricoides* infection among children in rural Senegal. *Trans R Soc Trop Med Hyg* 98: 397–399.
  34. Briand V, Watier L, Le Hesran JY, Garcia A, Cot M, 2005. Coinfection with *Plasmodium falciparum* and *Schistosoma haematobium*: protective effect of schistosomiasis on malaria in senegalese children? *Am J Trop Med Hyg* 72: 702–707.
  35. Lyke KE, Dicko A, Dabo A, Sangare L, Kone A, Coulibaly D, Guindo A, Traore K, Daou M, Diarra I, Szein MB, Plowe CV, Doumbo OK, 2005. Association of *Schistosoma haematobium* infection with protection against acute *Plasmodium falciparum* malaria in Malian children. *Am J Trop Med Hyg* 73: 1124–1130.
  36. Nacher M, Gay F, Singhasivanon P, Krudsood S, Treeprasertsuk S, Mazher D, Vouldoukis I, Looareesuwan S, 2000. *Ascaris lumbricoides* infection is associated with protection from cerebral malaria. *Parasite Immunol* 22: 107–113.
  37. Nacher M, Singhasivanon P, Silachamroon U, Treeprasertsuk S, Vannaphan S, Traore B, Gay F, Looareesuwan S, 2001. Helminth infections are associated with protection from malaria-related acute renal failure and jaundice in Thailand. *Am J Trop Med Hyg* 65: 834–836.
  38. Nacher M, Singhasivanon P, Treeprasertsuk S, Vannaphan S, Traore B, Looareesuwan S, Gay F, 2002. Intestinal helminths and malnutrition are independently associated with protection from cerebral malaria in Thailand. *Ann Trop Med Parasitol* 96: 5–13.
  39. Nacher M, Singhasivanon P, Traore B, Vannaphan S, Gay F, Chindanond D, Franetich JF, Mazier D, Looareesuwan S, 2002. Helminth infections are associated with protection from cerebral malaria and increased nitrogen derivatives concentrations in Thailand. *Am J Trop Med Hyg* 66: 304–309.
  40. WHO, 2002. *Reducing Risks, Promoting Healthy Life. The World Health Report 2002. Annex Table 3. Burden of Disease in DALYs by Cause, Sex and Mortality Stratum in WHO Regions, Estimates for 2001*. Geneva: World Health Organization.
  41. Brabin BJ, Hakimi M, Pelletier D, 2001. An analysis of anemia and pregnancy-related maternal mortality. *J Nutr* 131: 604S–614S.
  42. Grantham-McGregor S, Ani C, 2001. A review of studies on the effect of iron deficiency on cognitive development in children. *J Nutr* 131: 649S–666S.
  43. Korenromp EL, Armstrong-Schellenberg JR, Williams BG, Nahlen BL, Snow RW, 2004. Impact of malaria control on childhood anaemia in Africa—a quantitative review. *Trop Med Int Health* 9: 1050–1065.
  44. Yazdani M, Tadbiri M, Shakeri S, 2004. Maternal hemoglobin level, prematurity, and low birth weight. *Int J Gynaecol Obstet* 85: 163–164.
  45. Geerligs PD, Brabin BJ, Eggelte TA, 2003. Analysis of the effects of malaria chemoprophylaxis in children on haematological responses, morbidity and mortality. *Bull World Health Organ* 81: 205–216.
  46. McDevitt MA, Xie J, Gordeuk V, Bucala R, 2004. The anemia of malaria infection: role of inflammatory cytokines. *Curr Hematol Rep* 3: 97–106.
  47. Kurtzhals JA, Addae MM, Akanmori BD, Dunyo S, Koram KA, Appawu MA, Nkrumah FK, Hviid L, 1999. Anaemia caused by asymptomatic *Plasmodium falciparum* infection in semi-immune African schoolchildren. *Trans R Soc Trop Med Hyg* 93: 623–627.
  48. Stephenson LS, Latham MC, Kurz KM, Kinoti SN, Oduori ML, Crompton DW, 1985. Relationships of *Schistosoma haematobium*, hookworm and malarial infections and metrifonate treatment to hemoglobin level in Kenyan school children. *Am J Trop Med Hyg* 34: 519–528.
  49. Stoltzfus RJ, Chwaya HM, Tielsch JM, Schulze KJ, Albonico M, Savioli L, 1997. Epidemiology of iron deficiency anemia in Zanzibari schoolchildren: the importance of hookworms. *Am J Clin Nutr* 65: 153–159.
  50. Ezeamama AE, Friedman JF, Olveda RM, Acosta LP, Kurtis JD, Mor V, McGarvey ST, 2005. Functional significance of low-intensity polyparasite helminth infections in anemia. *J Infect Dis* 192: 2160–2170.
  51. Stephenson LS, Latham MC, Ottesen EA, 2000. Malnutrition and parasitic helminth infections. *Parasitology* 121 (Suppl): S23–S38.
  52. Akhwale WS, Lum JK, Kaneko A, Eto H, Obonyo C, Bjorkman A, Kobayakawa T, 2004. Anemia and malaria at different altitudes in the western highlands of Kenya. *Acta Trop* 91: 167–175.
  53. WHO Roll Back Malaria Department, 2005. *Malaria Control Today. Current WHO Recommendations*. Geneva: World Health Organization.
  54. Bradley-Moore AM, Greenwood BM, Bradley AK, Bartlett A, Bidwell DE, Voller A, Kirkwood BR, Gilles HM, 1985. Malaria chemoprophylaxis with chloroquine in young Nigerian children. I. Its effect on mortality, morbidity and the prevalence of malaria. *Ann Trop Med Parasitol* 79: 549–562.
  55. Menendez C, Kahigwa E, Hirt R, Vounatsou P, Aponte JJ, Font F, Acosta CJ, Schellenberg DM, Galindo CM, Kimario J, Urassa H, Brabin B, Smith TA, Kitua AY, Tanner M, Alonso PL, 1997. Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anaemia and malaria in Tanzanian infants. *Lancet* 350: 844–850.
  56. Lengeler C, 2004. Insecticide-treated bed nets and curtains for preventing malaria. *Cochrane Database Syst Rev* 2: CD000363.
  57. O'Meara WP, Breman JG, McKenzie FE, 2005. The promise and potential challenges of intermittent preventive treatment for malaria in infants (IPTi). *Malaria J* 4: 33.
  58. Cisse B, Sokhna C, Boulanger D, Milet J, Ba el H, Richardson K, Hallett R, Sutherland C, Simondon K, Simondon F, Alexander N, Gaye O, Targett G, Lines J, Greenwood B, Trape JF, 2006. Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial. *Lancet* 367: 659–667.
  59. Sagara I, Dicko A, Djimde A, Guindo O, Kone M, Tolo Y, Thera MA, Sogoba M, Fofana M, Ouattara A, Sissoko M, Jansen HF, Doumbo OK, 2006. A randomized trial of artesunate-sulfamethoxypyrazine-pyrimethamine versus artemether-lumefantrine for the treatment of uncomplicated *Plasmodium falciparum* malaria in Mali. *Am J Trop Med Hyg* 75: 630–636.
  60. Schellenberg D, Abdulla S, Roper C, 2006. Current issues for anti-malarial drugs to control *P. falciparum* malaria. *Curr Mol Med* 6: 253–260.
  61. Greenwood B, 2006. Intermittent preventive treatment—a new approach to the prevention of malaria in children in areas with seasonal malaria transmission. *Trop Med Int Health* 11: 983–991.
  62. Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, Tanner M, Mshinda H, Alonso PL, 2001. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. *Lancet* 357: 1471–1477.
  63. Chandramohan D, Owusu-Agyei S, Carneiro I, Awine T, Amponsa-Achiano K, Mensah N, Jaffar S, Baiden R, Hodgson A, Binka F, Greenwood B, 2005. Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. *BMJ* 331: 727–733.
  64. Stoltzfus RJ, Chway HM, Montresor A, Tielsch JM, Jape JK, Albonico M, Savioli L, 2004. Low dose daily iron supplementation improves iron status and appetite but not anemia, whereas quarterly anthelmintic treatment improves growth, appetite and anemia in Zanzibari preschool children. *J Nutr* 134: 348–356.
  65. Allen HE, Crompton DW, de Silva N, LoVerde PT, Olds GR, 2002. New policies for using anthelmintics in high risk groups. *Trends Parasitol* 18: 381–382.
  66. WHO, 2002. *Report of the WHO Informal Consultation on the Use of Praziquantel During Pregnancy/Lactation and Albendazole/Mebendazole in Children Under 24 Months*. Geneva: World Health Organization.
  67. von Seidlein L, Greenwood BM, 2003. Mass administrations of antimalarial drugs. *Trends Parasitol* 19: 452–460.
  68. Greenwood B, 2004. The use of anti-malarial drugs to prevent

- malaria in the population of malaria-endemic areas. *Am J Trop Med Hyg* 70: 1–7.
69. Bundy DAP, Lwin S, Osika JS, McLaughlin J, Pannenberg CO, 2000. What should schools do about malaria. *Parasitol Today* 16: 181–182.
  70. Brooker S, Guyatt H, Omumbo J, Shretta R, Drake L, Ouma J, 2000. Situation analysis of malaria in school-aged children in Kenya—what can be done? *Parasitol Today* 16: 183–186.
  71. Leenstra T, Phillips-Howard PA, Kariuki SK, Hawley WA, Alaii JA, Rosen DH, Oloo AJ, Nahlen BL, Kager PA, ter Kuile FO, 2003. Permethrin-treated bed nets in the prevention of malaria and anemia in adolescent schoolgirls in western Kenya. *Am J Trop Med Hyg* 68 (Suppl 4): 86–93.
  72. Magnussen P, Ndawi B, Sheshe AK, Byskov J, Mbwana K, 2001. Malaria diagnosis and treatment administered by teachers in primary schools in Tanzania. *Trop Med Int Health* 6: 273–279.
  73. Pasha O, Del Rosso J, Mukaka M, Marsh D, 2003. The effect of providing Fansidar (sulfadoxine-pyrimethamine) in schools on mortality in school age children in Malawi. *Lancet* 361: 577–578.
  74. Bundy DA, Medley GF, 1992. Immuno-epidemiology of human geohelminthiasis: ecological and immunological determinants of worm burden. *Parasitology* 104 (Suppl): S105–S119.
  75. Bundy DAP, 1988. Population ecology of intestinal helminth infections in human communities. *Philos Trans Roy Soc* 321: 405–420.
  76. Hotez PJ, Bundy DAP, Beegle K, Brooker S, Drake L, de Silva N, Montresor A, Engels D, Jukes M, Chitsulo L, Chow J, Laxminarayan R, Michaud C, Bethony J, Oliveira R, Xiao SH, Fenwick A, Savioli L, 2006. Helminth infections: soil-transmitted helminth infections and schistosomiasis. Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, eds. *Disease Control Priorities in Developing Countries*. New York: Oxford University Press, 467–497.
  77. Awasthi S, Bundy DAP, Savioli L, 2003. Helminthic infections. *BMJ* 23: 431–433.
  78. Laing AB, 1984. The impact of malaria chemoprophylaxis in Africa with special reference to Madagascar, Cameroon, and Senegal. *Bull World Health Organ* 62 (Suppl): 41–48.
  79. Shulman CE, Dorman EK, Cutts F, Kawuondo K, Bulmer JN, Peshu N, Marsh K, 1999. Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial. *Lancet* 353: 632–636.
  80. Rogerson SJ, Chaluluka E, Kanjala M, Mkundika P, Mhango C, Molyneux ME, 2000. Intermittent sulfadoxine-pyrimethamine in pregnancy: effectiveness against malaria morbidity in Blantyre, Malawi, in 1997–99. *Trans R Soc Trop Med Hyg* 94: 549–553.
  81. Newman RD, Parise ME, Slutsker L, Nahlen B, Steketee RW, 2003. Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in *Plasmodium falciparum*-endemic sub-Saharan Africa. *Trop Med Int Health* 8: 488–506.
  82. Gamble C, Ekwaru JP, ter Kuile FO, 2006. Insecticide-treated nets for preventing malaria in pregnancy. *Cochrane Database Syst Rev* 2: CD003755.
  83. WHO Schistosomiasis and Intestinal Parasites Unit, 1994. *Report of the WHO Informal Consultation on Hookworm Infection and Anaemia in Girls and Women*. Geneva: World Health Organization.
  84. Torlesse H, Hodges M, 2000. Anthelmintic treatment and haemoglobin concentrations during pregnancy. *Lancet* 356: 1083.
  85. Larocque R, Casapia M, Gotuzzo E, MacLean JD, Soto JC, Rahme E, Gyorkos TWD, 2006. A double-blind randomized controlled trial of antenatal mebendazole to reduce low birthweight in a hookworm-endemic area of Peru. *Trop Med Int Health* 11: 1485–1495.
  86. Christian P, Khatry S, West K, 2004. Antenatal anthelmintic treatment, birthweight, and infant survival in rural Nepal. *Lancet* 364: 981–983.
  87. Ajanga A, Lwambo NJ, Blair L, Nyandindi U, Fenwick A, Brooker S, 2006. *Schistosoma mansoni* in pregnancy and associations with anaemia in northwest Tanzania. *Trans R Soc Trop Med Hyg* 100: 59–63.
  88. Atukorala TM, de Silva LD, Dechering WH, Dassenaieke TS, Perera RS, 1994. Evaluation of effectiveness of iron-folate supplementation and anthelmintic therapy against anemia in pregnancy—a study in the plantation sector of Sri Lanka. *Am J Clin Nutr* 60: 286–292.
  89. Pedersen EM, Mukoko DA, 2002. Impact of insecticide-treated materials on filaria transmission by the various species of vector mosquito in Africa. *Ann Trop Med Parasitol* 96 (Suppl 2): S91–S95.
  90. Bockarie MJ, Tavul L, Kastens W, Michael E, Kazura JW, 2002. Impact of untreated bednets on prevalence of *Wuchereria bancrofti* transmitted by *Anopheles farauti* in Papua New Guinea. *Med Vet Entomol* 16: 116–119.
  91. Thylefors B, Alleman M, 2006. Towards the elimination of onchocerciasis. *Ann Trop Med Parasitol* 100: 733–746.
  92. Ottesen EA, 2006. Lymphatic filariasis: treatment, control and elimination. *Adv Parasitol* 61: 395–441.
  93. Blackburn BG, Eigege A, Gotau H, Gerlong G, Miri E, Hawley WA, Mathieu E, Richards F, 2006. Successful integration of insecticide-treated bed net distribution with mass drug administration in Central Nigeria. *Am J Trop Med Hyg* 75: 650–655.
  94. Hay S, Snow R, 2006. The Malaria Atlas Project: developing global maps of malaria risk. *PLoS Medicine* 3: e473.
  95. English M, Snow R, 2006. Iron and folic acid supplementation and malaria risk. *Lancet* 367: 90–91.
  96. Brooker S, Michael E, 2000. The potential of geographical information systems and remote sensing in the epidemiology and control of human helminth infections. *Adv Parasitol* 47: 245–288.
  97. Kelly-Hope LA, Diggle PJ, Rowlingson BS, Gyapong JO, Kyelem D, Coleman M, Thomson MC, Obsomer V, Lindsay SW, Hemingway J, Molyneux DH, 2006. Short communication: Negative spatial association between lymphatic filariasis and malaria in West Africa. *Trop Med Int Health* 11: 129–135.
  98. Raso G, Vounatsou P, Singer BH, N'Goran EK, Tanner M, Utzinger J, 2006. An integrated approach for risk profiling and spatial prediction of *Schistosoma mansoni*-hookworm coinfection. *Proc Natl Acad Sci USA* 103: 6934–6939.
  99. Folland S, Goodman AC, Stano M, 2004. *The Economics of Health and Health Care*. Upper Saddle River, NJ.
  100. Johns B, Torres TT, 2005. Costs of scaling up health interventions: a systematic review. *Health Policy Plan* 20: 1–13.
  101. Balk DL, Deichmann U, Yetman G, Pozzi F, Hay SI, Nelson A, 2006. Determining global population distribution, methods, applications and data. *Adv Parasitol* 62: 120–156.
  102. Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat, 2005. *World Population Prospects: The 2004 Revision and World Urbanization Prospects, The 2003 Revision*. Available at: <http://esa.un.org/unpp>. Accessed August 16, 2005.
  103. Ashford RW, Craig PS, Oppenheimer SJ, 1992. Polyparasitism on the Kenya coast. 1. Prevalence, and association between parasitic infections. *Ann Trop Med Parasitol* 86: 671–679.
  104. Kabatereine NB, Brooker S, Tukahebwa EM, Kazibwe F, Onapa AW, 2004. Epidemiology and geography of *Schistosoma mansoni* in Uganda: implications for planning control. *Trop Med Int Health* 9: 372–380.
  105. Quinnell RJ, Pritchard DI, Raiko A, Brown AP, Shaw MA, 2004. Immune responses in human necatoriasis: association between interleukin-5 responses and resistance to reinfection. *J Infect Dis* 190: 430–438.
  106. Geiger SM, Massara CL, Bethony J, Soboslay PT, Carvalho OS, Correa-Oliveira R, 2002. Cellular responses and cytokine profiles in *Ascaris lumbricoides* and *Trichuris trichiura* infected patients. *Parasite Immunol* 24: 499–509.
  107. Cooper PJ, Chico ME, Sandoval E, Espinel I, Guevara A, Kennedy MW, Urban JF Jr, Griffin GE, Nutman TB, 2000. Human infection with *Ascaris lumbricoides* is associated with a polarized cytokine response. *J Infect Dis* 182: 1207–1213.
  108. Quinnell RJ, Pritchard DI, Raiko A, Brown AP, Shaw M-A, 2004. Immune responses in human Necatoriasis: association between interleukin-5 responses and resistance to reinfection. *J Infect Dis* 190: 430–438.
  109. Bouharoun-Tayoun H, Druilhe P, 1992. *Plasmodium falciparum*

- malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. *Infect Immun* 60: 1473–1481.
110. Druilhe P, Sauzet JP, Sylla K, Roussilhon C, 2006. Worms can alter T cell responses and induce regulatory T cells to experimental malaria vaccines. *Vaccine* 24: 4902–4904.
  111. Jackson JA, Turner JD, Rentoul L, Faulkner H, Behnke JM, Hoyle M, Grencis RK, Else KJ, Kamgno J, Bradley JE, Boussinesq M, 2004. Cytokine response profiles predict species-specific infection patterns in human GI nematodes. *Int J Parasitol* 34: 1237–1244.
  112. Geiger SM, Massara CL, Bethony J, Soboslay PT, Correa-Oliveira R, 2004. Cellular responses and cytokine production in post-treatment hookworm patients from an endemic area in Brazil. *Clin Exp Immunol* 136: 334–340.
  113. Pit DS, Polderman AM, Schulz-Key H, Soboslay PT, 2000. Prenatal immune priming with helminth infections: parasite-specific cellular reactivity and Th1 and Th2 cytokine responses in neonates. *Allergy* 55: 732–739.
  114. Turner JD, Faulkner H, Kamgno J, Cormont F, Van Snick J, Else KJ, Grencis RK, Behnke JM, Boussinesq M, Bradley JE, 2003. Th2 cytokines are associated with reduced worm burdens in a human intestinal helminth infection. *J Infect Dis* 188: 1768–1775.
  115. Nacher M, 2004. Interactions between worm infections and malaria. *Clin Rev Allergy Immunol* 26: 85–92.
  116. Brooker S, Peshu N, Warn P, Mosobo M, Guyatt H, Marsh K, Snow R, 1999. Epidemiology of hookworm infection and its contribution to anaemia among pre-school children on the Kenyan coast. *Trans R Soc Trop Med Hyg* 93: 240–246.
  117. Shulman C, Graham W, Jilo H, Lowe B, New L, Obiero J, Snow R, Marsh K, 1996. Malaria is an important cause of anaemia in primigravidae, evidence from a district hospital in coastal Kenya. *Trans R Soc Trop Med Hyg* 90: 535–539.